Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 112.9% in January

Dermata Therapeutics, Inc. (NASDAQ:DRMA) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 294,200 shares, an increase of 112.9% from the January 15th total of 138,200 shares. Based on an average trading volume of 460,200 shares, the days-to-cover ratio is currently 0.6 days. Approximately 47.5% of the shares of the company are short sold.

Dermata Therapeutics Stock Performance

NASDAQ:DRMA opened at $1.19 on Friday. The business’s fifty day moving average is $1.25 and its 200 day moving average is $1.48. The firm has a market cap of $2.43 million, a price-to-earnings ratio of -0.07 and a beta of 0.67. Dermata Therapeutics has a 52-week low of $1.00 and a 52-week high of $7.62.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.